In the third and final episode, Desmond Cabrera, global lead for cell and gene therapy at Allucent, shares how small- and mid-sized companies can operationalize cell and gene therapy trials.

In the second episode, Pavle Vukojevic, a rheumatologist turned clinical researcher who is now the chief scientific officer at Allucent, explains why multinational clinical trials are key to bringing novel therapies to market.

In the first episode, MerriBeth Adams, PhD, senior vice president of the consulting business unit at Allucent, discusses how developing a regulatory strategy can save you time and money while setting you up for success in bringing treatments to patients. We also dive into the critical importance of a gap analysis and the characteristics of an effective regulatory strategy.